Nuvasive Logo
US6707041058
A0CAYR
NUVA

Nuvasive

Loading quotes...

Forecast

The analysts' average price target is €52.46 (+42.36%). The median is €54.27 (+47.27%).

Buy
  13
Hold
  21
Sell
  1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Nuvasive had revenue of €1.12B and net profit of €37.67M
(EUR) 2022
YoY
Revenue 1.12B 11.87%
Gross profit 806.8M 12.33%
Net profit 37.67M 166.84%
EBITDA 138.65M 12.85%

Fundamentals

Metric Value
Market capitalization
€1.89B
Number of shares
52.45M
52-week high/low
€44.80 - €31.81
Dividends No
Beta
1.07
P/E ratio
50.96
PEG ratio
0.17
P/B ratio
2.62
P/S ratio
1.73

Company profile

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Name
Nuvasive
CEO
J. Christopher Barry
Headquarters San Diego, ca
USA
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
05/13/2004
Employees 3,000

Ticker symbols

Exchange Symbol
NASDAQ
NUVA
🍪

Parqet  uses cookies. Learn more